Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10

Chemico-Biological Interactions

Volumn 234, Issue , 2015, Pages 290-296

  Cousido Siah, Alexandra ^a   Ruiz, Francesc X ^a   Crespo, Isidro ^b   Porté, Sergio ^b   Mitschler, André ^a   Parés, Xavier ^b   Podjarny, Alberto ^a   Farrés, Jaume ^b  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AKR1B10 PROTEIN, HUMAN; ALDEHYDE REDUCTASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SULINDAC;

ANTAGONISTS AND INHIBITORS; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION;

ALDEHYDE REDUCTASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; NADP; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; STRUCTURE-ACTIVITY RELATIONSHIP; SULINDAC;

EID: 84933502802     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.12.018     Document Type: Article

References (39)

1. Y. Jin, and T.M. Penning Aldo-keto reductases and bioactivation/detoxication Annu. Rev. Pharmacol. Toxicol. 47 2007 263 292
2. O.A. Barski, S.M. Tipparaju, and A. Bhatnagar The aldo-keto reductase superfamily and its role in drug metabolism and detoxification Drug Metab. Rev. 40 2008 553 624
3. F.X. Ruiz, S. Porté, X. Parés, and J. Farrés Biological role of aldo-keto reductases in retinoic acid biosynthesis and signaling Front. Pharmacol. 3 2012 58
4. P.J. Oates Aldose reductase, still a compelling target for diabetic neuropathy Curr. Drug Targets. 9 2008 14 36
5. B. Crosas, D.J. Hyndman, O. Gallego, S. Martras, X. Parés, T.G. Flynn, and J. Farrés Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism Biochem. J. 373 2003 973 979
6. F.X. Ruiz, O. Gallego, A. Ardèvol, A. Moro, M. Domínguez, S. Alvarez, R. Alvarez, A.R. de Lera, C. Rovira, I. Fita, X. Parés, and J. Farrés Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels Chem. Biol. Interact. 178 2009 171 177
7. T. Matsunaga, Y. Wada, S. Endo, M. Soda, O. El-Kabbani, and A. Hara Aldo-keto reductase 1b10 and its role in proliferation capacity of drug-resistant cancers Front. Pharmacol. 3 2012 5
8. D. Brunell, D. Sagher, S. Kesaraju, N. Brot, and H. Weissbach Studies on the metabolism and biological activity of the epimers of sulindac Drug Metab. Dispos. 39 2011 1014 1021
9. E. Gurpinar, W.E. Grizzle, and G.A. Piazza NSAIDs inhibit tumorigenesis, but how? Clin. Cancer Res. 20 2014 1104 1113
10. N. Li, Y. Xi, H.N. Tinsley, E. Gurpinar, B.D. Gary, B. Zhu, Y. Li, X. Chen, A.B. Keeton, A.H. Abadi, M.P. Moyer, W.E. Grizzle, W.C. Chang, M.L. Clapper, and G.A. Piazza Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling Mol. Cancer Ther. 12 2013 1848 1859
11. C.S. Williams, A.P. Goldman, H. Sheng, J.D. Morrow, and R.N. DuBois Sulindac sulfide, but not sulindac sulfone inhibits colorectal cancer growth Neoplasia 1 1999 170 176
12. H. Li, A.L. Yang, Y.T. Chung, W. Zhang, J. Liao, and G.-Y. Yang Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10) Carcinogenesis 34 2013 2090 2098
13. H. Akashi, H.J. Han, M. Iizaka, and Y. Nakamura Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac Int. J. Cancer. 88 2000 873 880
14. E. Gurpinar, W.E. Grizzle, and G.A. Piazza COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs Front. Oncol. 3 2013 181
15. H. Zhou, W. Liu, Y. Su, Z. Wei, J. Liu, S.K. Kolluri, H. Wu, Y. Cao, J. Chen, Y. Wu, T. Yan, X. Cao, W. Gao, A. Molotkov, F. Jiang, W.G. Li, B. Lin, H.P. Zhang, J. Yu, S.P. Luo, J.Z. Zeng, G. Duester, P.Q. Huang, and X.K. Zhang NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling Cancer Cell. 17 2010 560 573
16. E. Gurpinar, W.E. Grizzle, J.J. Shacka, B.J. Mader, N. Li, N.A. Piazza, S. Russo, A.B. Keeton, and G.A. Piazza A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy Mol. Cancer Ther. 12 2013 663 674
17. H.-J. Lee, N.X. Wang, D.-L. Shi, and J.J. Zheng Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein dishevelled Angew. Chem. Int. Ed. Engl. 48 2009 6448 6452
18. W. Sun, C. Gerhardinger, Z. Dagher, T. Hoehn, and M. Lorenzi Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects Diabetes 54 2005 3418 3426
19. A. Sethi, H.S. Parmar, and A. Kumar The effect of aspirin on atherogenic diet-induced diabetes mellitus Basic Clin. Pharmacol. Toxicol. 108 2011 371 377
20. X. Zheng, L. Zhang, J. Zhai, Y. Chen, H. Luo, and X. Hu The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase FEBS Lett. 586 2012 55 59
21. J.U. Flanagan, Y. Yosaatmadja, R.M. Teague, M.Z. Chai, A.P. Turnbull, and C.J. Squire Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3 PLoS One 7 2012 e43965
22. M. Chen, A.O. Adeniji, B.M. Twenter, J.D. Winkler, D.W. Christianson, and T.M. Penning Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer Bioorg. Med. Chem. Lett. 22 2012 3492 3497
23. T.M. Penning, and M.C. Byrns Steroid hormone transforming aldo-keto reductases and cancer Ann. N. Y. Acad. Sci. 1155 2009 33 42
24. S. Endo, T. Matsunaga, M. Soda, K. Tajima, H.-T. Zhao, O. El-Kabbani, and A. Hara Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid Biol. Pharm. Bull. 33 2010 886 890
25. H. Steuber An old NSAID revisited: crystal structure of aldose reductase in complex with sulindac at 1.0 Å supports a novel mechanism for its anticancer and antiproliferative effects ChemMedChem 6 2011 2155 2157
26. A.J. Liedtke, A.O. Adeniji, M. Chen, M.C. Byrns, Y. Jin, D.W. Christianson, L.J. Marnett, and T.M. Penning Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer J. Med. Chem. 56 2013 2429 2446
27. V. Lamour, P. Barth, H. Rogniaux, A. Poterszman, E. Howard, A. Mitschler, D.A. Myles, and A. Podjarny Production of crystals of human aldose reductase with very high resolution diffraction Acta Crystallogr. D. Biol. Crystallogr. 55 1999 721 723
28. O. Gallego, F.X. Ruiz, A. Ardèvol, M. Domínguez, R. Alvarez, A.R. de Lera, C. Rovira, J. Farrés, I. Fita, and X. Parés Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10 Proc. Natl. Acad. Sci. U.S.A. 104 2007 20764 20769
29. A. Cousido-Siah, F.X. Ruiz, A. Mitschler, S. Porté, Á.R. de Lera, M.J. Martín, S. Manzanaro, J.A. de la Fuente, F. Terwesten, M. Betz, G. Klebe, J. Farrés, X. Parés, and A. Podjarny Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design Acta Crystallogr. D. Biol. Crystallogr. 70 2014 889 903
30. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode Macromol. Crystallogr. Pt A. 276 1997 307 326
31. A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read Phaser crystallographic software J. Appl. Crystallogr. 40 2007 658 674
32. P. Emsley, B. Lohkamp, W.G. Scott, and K. Cowtan Features and development of coot Acta Crystallogr. D. Biol. Crystallogr. 66 2010 486 501
33. G.N. Murshudov, P. Skubák, A.A. Lebedev, N.S. Pannu, R.A. Steiner, R.A. Nicholls, M.D. Winn, F. Long, and A.A. Vagin REFMAC5 for the refinement of macromolecular crystal structures Acta Crystallogr. D. Biol. Crystallogr. 67 2011 355 367
34. P.D. Adams, P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, A.J. McCoy, N.W. Moriarty, R. Oeffner, R.J. Read, D.C. Richardson, J.S. Richardson, T.C. Terwilliger, and P.H. Zwart PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D. Biol. Crystallogr. 66 2010 213 221
35. A. Urzhumtsev, F. Tête-Favier, a Mitschler, J. Barbanton, P. Barth, L. Urzhumtseva, J.F. Biellmann, A. Podjarny, and D. Moras A "specificity" pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil Structure 5 1997 601 612
36. C. Bissantz, B. Kuhn, and M. Stahl A medicinal chemist's guide to molecular interactions J. Med. Chem. 53 2010 5061 5084
37. F.X. Ruiz, A. Cousido-Siah, A. Mitschler, J. Farrés, X. Parés, and A. Podjarny X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity Chem. Biol. Interact. 202 2013 178 185
38. S. Porté, F.X. Ruiz, J. Giménez, I. Molist, S. Alvarez, M. Domínguez, R. Alvarez, A.R. de Lera, X. Parés, and J. Farrés Aldo-keto reductases in retinoid metabolism: search for substrate specificity and inhibitor selectivity Chem. Biol. Interact. 202 2013 186 194
39. M. Jung, A.F. Wahl, W. Neupert, G. Geisslinger, and P.D. Senter Synthesis and activity of fluorinated derivatives of sulindac sulphide and sulindac sulphone Pharm. Pharmacol. Commun. 6 2000 217 221